AUG 6·SEC EDGARLow
Horn Kinney sold $2.3M of IMNM
Horn Kinney (CHIEF BUSINESS OFFICER) sold 90,616 shares of Immunome Inc. (IMNM) at $25.09 ($2.27M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$IMNM
Immunome Inc.
Price · $IMNMvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $IMNM in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $2.3M 1 txs
Horn Kinney1× · $2.3M
10b5-1 plan100%
Top stories · $IMNMMore →
JUL 12·yahoo.com
What This Immunome Sale Means a Day Before a Big FDA Milestone
Immunome reported $582.7M cash as of March 31 and a Q1 net loss of $53.8M. The article says an insider sale occurred via a preset plan as the FDA accepted Immunome’s varegacestat NDA for review. It cites an FDA decision date of April 28, 2027, based on Phase 3 data showing an 84% lower risk of progression.
JUL 7·SEC EDGAR
Barchas Isaac sold $2.4M of IMNM (indirect holdings)
Barchas Isaac sold 100,000 indirectly-held shares of Immunome Inc. (IMNM) at an average of $24.13 ($24.11–$24.20, $2.41M total) across 2 trades over 2026-07-06 to 2026-07-07 under a Rule 10b5-1 trading plan.
IMNM sentiment & insider activity
Recent IMNM coverage spans insider activity, regulation and corporate actions.
In the last 30 days, IMNM insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($2.3M). The most active reporter was Horn Kinney, CHIEF BUSINESS OFFICER, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving IMNM
This is an insider open-market sale, not a company fundamental update, but it can modestly affect near-term sentiment.
FDA acceptance and a fixed PDUFA-style decision date are the key tradable catalyst, while the article frames the concurrent insider sale as non-alarming.
This is an insider sale disclosure; it may slightly pressure sentiment but is not a fundamental catalyst by itself.
This is a routine insider-sale disclosure; it may slightly affect sentiment but does not indicate a new operational or financial catalyst.
This is an insider sale disclosure, not a fundamental company update. It may slightly affect sentiment, but it is unlikely to change near-term valuation absent other news.
alphai scores every news story that mentions IMNM with an AI model for sentiment and relevance, and aggregates insider trades from Immunome Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $IMNM
Score
Horn Kinney sold $2.3M of IMNM
Horn Kinney (CHIEF BUSINESS OFFICER) sold 90,616 shares of Immunome Inc. (IMNM) at $25.09 ($2.27M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
2 min readWhat This Immunome Sale Means a Day Before a Big FDA Milestone
Immunome reported $582.7M cash as of March 31 and a Q1 net loss of $53.8M. The article says an insider sale occurred via a preset plan as the FDA accepted Immunome’s varegacestat NDA for review. It cites an FDA decision date of April 28, 2027, based on Phase 3 data showing an 84% lower risk of progression.
7 min readBarchas Isaac sold $2.4M of IMNM (indirect holdings)
Barchas Isaac sold 100,000 indirectly-held shares of Immunome Inc. (IMNM) at an average of $24.13 ($24.11–$24.20, $2.41M total) across 2 trades over 2026-07-06 to 2026-07-07 under a Rule 10b5-1 trading plan.
1 min readLechleider Robert sold $1.2M of IMNM
Lechleider Robert (Chief Medical Officer) sold 55,000 shares of Immunome Inc. (IMNM) at an average of $22.62 ($21.95–$23.44, $1.24M total) across 3 trades on 2026-07-02 under a Rule 10b5-1 trading plan.
2 min readBarchas Isaac sold $4.4M of IMNM (indirect holdings)
Barchas Isaac sold 201,050 indirectly-held shares of Immunome Inc. (IMNM) at an average of $21.85 ($21.12–$23.33, $4.39M total) across 3 trades over 2026-06-30 to 2026-07-02 under a Rule 10b5-1 trading plan.
2 min readLechleider Robert sold $1.1M of IMNM
Lechleider Robert (Chief Medical Officer) sold 55,000 shares of Immunome Inc. (IMNM) at an average of $19.85 ($19.56–$20.66, $1.09M total) across 2 trades on 2026-06-25 under a Rule 10b5-1 trading plan.
2 min readRosett Max sold $1.1M of IMNM
Rosett Max (Chief Financial Officer) sold 60,000 shares of Immunome Inc. (IMNM) at $18.23 ($1.09M total) on 2026-06-15 under a Rule 10b5-1 trading plan.
1 min readImmunome Inc. (IMNM): Submission of Matters to a Vote of Security Holders
Immunome Inc. (IMNM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001472012 0001472012 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2
2 min readBIENAIME JEAN JACQUES purchased $204K of IMNM
BIENAIME JEAN JACQUES purchased 10,500 shares of Immunome Inc. (IMNM) at an average of $19.45 ($19.27–$19.48, $0.20M total) across 3 trades on 2026-06-05.
1 min readBIENAIME JEAN JACQUES sold $204K of IMNM
BIENAIME JEAN JACQUES sold 10,500 shares of Immunome Inc. (IMNM) at an average of $19.41 ($19.41–$19.44, $0.20M total) across 2 trades on 2026-06-05.
1 min read